Wall Street analysts predict that Zimmer Biomet Holdings Inc (NYSE:ZBH) will report $1.87 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have provided estimates for Zimmer Biomet’s earnings, with estimates ranging from $1.83 to $1.90. Zimmer Biomet reported earnings per share of $2.13 in the same quarter last year, which would indicate a negative year-over-year growth rate of 12.2%. The company is expected to report its next quarterly earnings results on Thursday, April 26th.
According to Zacks, analysts expect that Zimmer Biomet will report full year earnings of $7.82 per share for the current fiscal year, with EPS estimates ranging from $7.68 to $8.25. For the next financial year, analysts anticipate that the firm will post earnings of $8.37 per share, with EPS estimates ranging from $8.00 to $9.05. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Zimmer Biomet.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.10. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The company had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.03 billion. During the same quarter in the prior year, the company earned $2.14 EPS. Zimmer Biomet’s quarterly revenue was up 3.0% on a year-over-year basis.
Zimmer Biomet (ZBH) opened at $120.48 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.52 and a quick ratio of 0.83. Zimmer Biomet has a fifty-two week low of $108.03 and a fifty-two week high of $133.49. The firm has a market cap of $24,393.96, a P/E ratio of 15.00, a P/E/G ratio of 2.12 and a beta of 1.08.
The firm also recently announced a quarterly dividend, which was paid on Monday, January 29th. Stockholders of record on Friday, December 29th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. Zimmer Biomet’s dividend payout ratio (DPR) is 10.65%.
In other news, VP Chad F. Phipps sold 20,826 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $115.95, for a total transaction of $2,414,774.70. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.07% of the company’s stock.
Several large investors have recently made changes to their positions in ZBH. Bank of Nova Scotia Trust Co. purchased a new position in Zimmer Biomet in the 3rd quarter valued at $112,000. FNY Managed Accounts LLC purchased a new position in Zimmer Biomet in the 3rd quarter valued at $117,000. Cerebellum GP LLC purchased a new position in Zimmer Biomet in the 4th quarter valued at $133,000. We Are One Seven LLC purchased a new position in Zimmer Biomet in the 4th quarter valued at $137,000. Finally, Steward Partners Investment Advisory LLC purchased a new position in Zimmer Biomet in the 3rd quarter valued at $140,000. Hedge funds and other institutional investors own 88.18% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2018/02/20/1-87-eps-expected-for-zimmer-biomet-holdings-inc-zbh-this-quarter.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.